Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy. - Wikidata - wikimedia - TriplyDB

Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.

Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.

http://www.wikidata.org/entity/Q34784085

about

Matrix Metalloproteinases in Non-Neoplastic Disorders.Present and future in the treatment of diabetic kidney disease Imbalanced matrix metalloproteinases in cardiovascular complications of end-stage kidney disease: a potential pharmacological target Matrix metalloproteinases in kidney homeostasis and diseases Emerging targets in neuroinflammation-driven chronic pain Matrix Metalloproteinase Inhibition Mitigates Renovascular Remodeling in Salt-Sensitive Hypertension.To cleave or not to cleave: role of ADAM17 in cell proliferation in PKD.Reduction of mouse atherosclerosis by urokinase inhibition or with a limited-spectrum matrix metalloproteinase inhibitor.Fluorescence dilution technique for measurement of albumin reflection coefficient in isolated glomeruli.Heterozygous knockout of transforming growth factor-β1 protects Dahl S rats against high salt-induced renal injury.Implications of treatment that target protective mechanisms against diabetic nephropathy Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats Epidermal growth factors in the kidney and relationship to hypertension.Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9.Comparison of the Development Diabetic Induced Renal Disease in Strains of Goto-Kakizaki Rats Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE.Emerging drugs for managing kidney disease in patients with diabetes.Therapeutic approaches to diabetic nephropathy--beyond the RAS.Differential effects of Smad3 targeting in a murine model of chronic kidney disease Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic?Loss of TIMP3 selectively exacerbates diabetic nephropathy.Ets in the Kidney-Unraveling the Molecular Mechanism Underlying Renal Damage in Salt-Sensitive Hypertension.

P2860

Q26741827-1D6DAA40-9609-47C9-AEF9-591DC13458C5 Q26864133-F67EECDD-C8B6-40EE-A259-5C6E8C59EE2A Q26864722-B0BE24E1-BCA2-443D-89A6-A632C769E1BC Q27004621-35343A75-941C-4900-AEBA-DA2A30A1392A Q28242435-B560C266-86F4-4C64-AE27-AA217E517C4B Q30446389-C968F92E-CD1B-49B1-830C-BF2511E81845 Q34200977-71402F13-FCA4-4DEE-A2CE-58FB6156497C Q35152774-5779B129-23D4-438B-BB45-B13916F65301 Q36382099-07672738-9DA4-45A7-A36A-DE8678EA0A69 Q36599920-88577BCD-26DF-4358-BDD8-1E2589F1D300 Q36645971-D9928891-1A8D-48A4-9046-1F2BE92785D6 Q36852567-043EED95-53AF-4DE1-A5B1-F3321FDFE78B Q37051477-AA2264F1-CA51-4F9F-9DAF-EEA08C5FA665 Q37242419-A373350C-80A6-4018-9F70-8137710A2E5A Q37368852-50CF168A-8908-427C-9AAD-84620D50C60D Q37541225-8EFEECAB-2230-438E-9CCE-BA2F1F9DD4B2 Q38075029-859BFD68-F126-4640-824B-85D056CA0435 Q38209811-A9A13603-AC81-4C95-8F28-649A8559F617 Q38568865-29C45039-9BEB-47AA-99F9-F6DA303AE1B4 Q38942962-3C93AA31-6D05-4C07-9F35-AE6B03332997 Q42402000-1CAF990F-21FB-4BA1-B6FA-34C352F1F712 Q45070233-72546D29-C374-4A89-935E-9499A9FC2BA6

P2860

Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.

http://www.wikidata.org/entity/Q34784085

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.

@ast

Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.

@en

Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.

@nl

type

label

Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.

@ast

Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.

@en

Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.

@nl

prefLabel

Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.

@ast

Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.

@en

Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.

@nl

P1433

Q34784085-845F4CA6-7F6F-4ACD-AE7F-82B53C115014

P1476

Q34784085-56BB3B14-9ED5-4A37-BB75-C6061A300808

P2093

Q34784085-1CD4BE20-68E5-43B9-95DD-861953F4EEF5

Q34784085-6CBFC5FB-35D5-4D4A-93D4-079520EC9AB5

Q34784085-825D1AE8-E24D-4091-A9AC-5B115449A4BD

Q34784085-9F169287-7496-4817-A45F-C228C4D3E3A5

Q34784085-A07F06BB-4A4A-4C3A-B467-938EB040A3E3

Q34784085-C4D85E68-ED72-45DC-B039-EEC00CE553D3

Q34784085-D5B5ECE1-C72F-4FDF-AAC1-7D2E08922E30

P2860

Q34784085-0282D6B3-11DF-42B6-817C-D96374849504

Q34784085-04CB57AD-11B1-438A-9CB0-C53253E89EE8

Q34784085-0605F3DC-CE44-4E46-B410-1B4CADFAFE36

Q34784085-06E7C42E-73E6-4D96-B86C-AF44C3452C76

Q34784085-0837EC61-EAD2-470C-B03E-5D03291F4164

Q34784085-0B27F094-143A-44A7-8023-276C459B5C16

Q34784085-0B581326-7ADC-4C96-9A6B-86B4FF2CB7DA

Q34784085-0F8A419A-95C0-4D3C-9CDE-8BD03EDD80E0

Q34784085-14AFCEB1-09A8-4A3F-A67C-134F26B2BF94

Q34784085-16381C63-E2CF-4123-B27A-746D32FD08A8

P304

Q34784085-BCA3EC66-A4FE-4F78-A40F-F2EBF647D1F9

P31

Q34784085-2F6E3370-0B9A-4FE0-974C-C45A20515962

P356

Q34784085-D788C3D4-2C94-43FE-A979-94629E8FC25A

P433

Q34784085-BB90933E-F2CF-44B5-B8B8-79892663A168

P478

Q34784085-2DEEADE4-6BA6-491B-B157-2A36CADAAE12

P577

Q34784085-945739BC-45DF-4D8D-8333-FF1277BFCACF

P698

Q34784085-D8742BD5-5F93-4F74-9A50-D537E2C76306

P932

Q34784085-36F40FD1-50BD-40B9-9E33-C2623C133C18

P356

AJPRENAL.00262.2010

P1433

American Journal of Physiology - Renal Physiology

P1476

Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.

@en

P2093

Annette Dahly-Vernon

http://www.w3.org/2001/XMLSchema#string

Jan M Williams

http://www.w3.org/2001/XMLSchema#string

Jin Zhang

http://www.w3.org/2001/XMLSchema#string

Michael Yakes

http://www.w3.org/2001/XMLSchema#string

Paula North

http://www.w3.org/2001/XMLSchema#string

Richard J Roman

http://www.w3.org/2001/XMLSchema#string

Steven Lacy

http://www.w3.org/2001/XMLSchema#string

P2860

Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells

The first stage of transforming growth factor beta1 activation is release of the large latent complex from the extracellular matrix of growth plate chondrocytes by matrix vesicle stromelysin-1 (MMP-3)

End-stage renal disease in the United States: an update from the United States Renal Data System.

Transforming growth factor beta-angiotensin II interaction: implications for cardiac and renal disease.

TGF-beta in diabetic kidney disease: role of novel signaling pathways.

Transforming growth factor-beta, basement membrane, and epithelial-mesenchymal transdifferentiation: implications for fibrosis in kidney disease.

TGF-beta signaling in renal disease.

Dissection of a genetic locus influencing renal function in the rat and its concordance with kidney disease loci on human chromosome 1q21

Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.

Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats

P304

F983-98

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPRENAL.00262.2010

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

300

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21228113

http://www.w3.org/2001/XMLSchema#string

P932

3074997

http://www.w3.org/2001/XMLSchema#string